Esmirtazapine

From Self-sufficiency
Revision as of 21:24, 29 July 2010 by PotatoBot (Talk) (Stub sorting and placement of stub template(s): nervous-system-drug-stub)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Esmirtazapine
File:(S)-Mirtazapin Structural Formulae.png
Systematic (IUPAC) name
(S)-1,2,3,4,10,14b-hexahydro-2-methylpyrazino(2,1-a)pyrido(2,3-c)(2)benzazepine
Clinical data
Routes of
administration
Oral
Legal status
Legal status
  • Uncontrolled
Pharmacokinetic data
Metabolism Liver (CYP2D6)[1]
Identifiers
CAS Number 61337-87-9
ATC code none
PubChem CID 6451144
ChemSpider 4953625
Chemical data
Formula C21H23N3O4
Molar mass 381.43 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Physical data
Melting point 114 to 116 °C (237 to 241 °F)
Solubility in water Soluble in methanol and chloroform mg/mL (20 °C)
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Esmirtazapine (ORG-50,081) is a drug which is under development by Organon for the treatment of insomnia and vasomotor symptoms (e.g., hot flashes) associated with menopause.[2][3][4][5] As of 2009 it is in phase III clinical trials.[2] Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses similar overall pharmacology, including inverse agonist actions at H1 and 5-HT2 receptors and antagonist actions at α2-adrenergic receptors.[2][6]

See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />



fr:Esmirtazapine
  1. "A population analysis on the effects of the CYP2D6 deficiency on pharmacokinetics and exposure of esmirtazapine in healthy volunteers" (PDF). 
  2. 2.0 2.1 2.2 "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD -- Neurotransmitter.net". 
  3. "A Long-Term Safety Study of Org 50081 in Elderly Outpatients With Chronic Primary Insomnia (176005)(P05697) - Full Text View - ClinicalTrials.gov". 
  4. Teegarden BR, Al Shamma H, Xiong Y (2008). "5-HT(2A) inverse-agonists for the treatment of insomnia". Current Topics in Medicinal Chemistry. 8 (11): 969–76. PMID 18673166. 
  5. Lua error in package.lua at line 80: module 'Module:Citation/CS1/Suggestions' not found.
  6. Depression and bipolar disorder: Stahl's essential psychopharmacology. Cambridge, UK: Cambridge University Press. 2008. ISBN 0-521-88663-5.